Ranibizumab no better than saline for vitreous hemorrhage

Ranibizumab no better than saline for vitreous hemorrhage
For patients with vitreous hemorrhage from proliferative diabetic retinopathy, the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, with little difference seen between the two treatments, according to a study published online Jan. 31 in JAMA Ophthalmology.

(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, with little difference seen between the two treatments, according to a study published online Jan. 31 in JAMA Ophthalmology.

Abdhish R. Bhavsar, M.D., from the Retina Center of Minnesota in Minneapolis, along with colleagues from the Clinical Research Network, compared intravitreal ranibizumab with intravitreal saline injections for their effect on vitrectomy rates for vitreous hemorrhage from PDR in a phase 3, randomized clinical trial involving 261 eyes of 261 participants who were at least 18 years of age and had type 1 or 2 diabetes. One hundred twenty-five eyes were randomly allocated to receive 0.5-mg intravitreal ranibizumab, and 136 were randomized to receive intravitreal saline at baseline and at four and eight weeks.

At 16 weeks, the researchers found that the cumulative probability of vitrectomy was 12 percent with ranibizumab and 17 percent with saline, and that the cumulative probability of complete panretinal photocoagulation without vitrectomy was 44 and 31 percent, respectively (P = 0.05). From baseline to 12 weeks, the mean improvement was 22 and 16 letters, respectively (P = 0.04). Within 16 weeks, 6 and 17 percent, respectively, experienced recurrent vitreous hemorrhage (P = 0.01). Endophthalmitis developed in one eye following .

"This study suggests little likelihood of a clinically important difference between ranibizumab and saline on the rate of vitrectomy by 16 weeks in eyes with vitreous hemorrhage from PDR," the authors write. "Whether vitrectomy rates after saline or ranibizumab injection are different than observation alone cannot be determined from this study."

provided the and partially funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Long-term ranibizumab beneficial for macular edema

date Oct 11, 2012

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity ...

Steroid injections may slow diabetes-related eye disease

date Dec 15, 2009

Injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of diabetes that can cause vision loss and blindness, according to a report in the December issue of ...

Vitreolytic ocriplasmin resolves vitreomacular traction

date Aug 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...

Recommended for you

Children's eye injuries from nonpowder guns on the rise

date Apr 27, 2015

Over 3000 children were treated in U.S. emergency departments in 2012 for eye injuries related to paintball guns, airsoft guns, BB guns and pellet guns, which are popular non-powder guns. A new report published ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.